NeuroDerm

Company Overview

Snapshot

Founded in March 2003, NeuroDerm operates with 51–200 employees. The company secured funding across 3 rounds from 2 investors, raising a total of $63.5 million. A significant milestone occurred in July 2017 when NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation for $1.1 billion in cash.

Business overview

NeuroDerm specializes in developing drug-device combination solutions for central nervous system disorders. The company integrates proprietary pharmaceutical formulations, advanced delivery systems, and digital health solutions to reduce disease burden and improve patient quality of life. Its flagship product, ND0612, is in late-stage development for Parkinson's disease patients experiencing motor fluctuations, offering a user-friendly system for continuous subcutaneous infusion of levodopa/carbidopa. NeuroDerm operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals market with its focus on neurology and drug discovery and development.

Strategic signal

In January 2023, NeuroDerm announced highly positive results from its pivotal Phase III BouNDless trial evaluating ND0612 for Parkinson's disease patients with motor fluctuations. This successful trial outcome is a strong validation of the company's drug-device combination approach, signaling significant progress towards regulatory approval and potential market entry for a critical treatment in neurology. For investors, this demonstrates the company's ability to advance its pipeline through rigorous clinical development, enhancing its value proposition in the biopharmaceutical landscape.

Company Intelligence Q&A

What was a significant financial event for NeuroDerm in 2017?

In July 2017, NeuroDerm entered into a definitive agreement to be acquired by Mitsubishi Tanabe Pharma Corporation for $1.1 billion in cash.

What was the outcome of the Phase III BouNDless trial for ND0612?

In January 2023, NeuroDerm announced highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in Parkinson's disease patients with motor fluctuations.

When did NeuroDerm initiate its Phase 3 clinical trial for ND0612 in the United States?

In August 2019, NeuroDerm initiated a Phase 3 clinical trial in the United States evaluating continuous subcutaneous carbidopa/levodopa (ND0612) for Parkinson's disease with motor fluctuations.

What was the result of NeuroDerm's trial results in March 2017?

In March 2017, NeuroDerm's stock price increased following successful trial results, as reported by Globes.co.il.

When did NeuroDerm conduct a secondary offering on Nasdaq?

In July 2015, NeuroDerm raised $67 million in a Nasdaq secondary offering.